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a b s t r a c t
Allogeneic hematopoietic stem cell transplantation (HSCT) following myeloablative (con-
ventional) conditioning regimen is associated with a high incidence of transplant-related
morbidity and mortality, limiting its use to younger patients without medical co-morbid-
ities. Over the past few years, it has become more evident that the alloreactivity of trans-
planted donor immunocompetent cells against host tumor cells (graft-versus-tumor
effects, GVT effects) plays a major role in eradicating malignancies after allogeneic HSCT.
Based on these observations, several groups of investigators have developed reduced inten-
sity conditioning (RIC) regimens allowing patients who are ineligible for conventional
HSCT to beneﬁt from the potentially curative GVT effects of allogeneic transplantation. Ret-
rospective studies have suggested that, in comparison with myeloablative allogeneic HSCT,
in patients aged 40–60 years, RIC HSCT was associated with a higher risk of relapse but a
lower incidence of transplant-related mortality leading to similar progression-free and
overall survivals. Prospective studies are ongoing to deﬁne which patients might most ben-
eﬁt from RIC HSCT, and to increase the anti-tumoral activity of the procedure while reduc-
ing the incidence and the severity of acute graft-versus-host disease (GVHD). In this article,
we review the current status and perspectives of RIC HSCT.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Allogeneic hematopoietic stem cell transplantation
(HSCT) followingmyeloablative conditioning is an effective
therapy for many patients with hematological diseases.
However, myeloablative conditioning regimens have been
associated with signiﬁcant morbidity and mortality, partic-
ularly in patients older than 45 years, those affected by
other comorbidities or who have been heavily pretreated
(more than two lines of conventional chemotherapy or
previous HSCT). This is why conventional allogeneic HSCT
has been restricted to younger patients (<50–55 years of
age) in good medical condition, whereas the median
patient age at diagnosis for many hematological malignan-
cies is over 50 years [1].
Allogeneic HSCT initially relied on maximally tolerated
doses of systemic chemo-radiotherapy to eradicate malig-
nant cells, while hematopoietic stem cells (HSC) were in-
fused to rescue patients from lethal myeloablation that
occured as side effect [1]. However, it was quickly recog-
nized that the allograft itself conferred immune-mediated
antileukemic effects, termed graft-versus-tumor (GVT) ef-
fects [2]. The recognition of the importance of GVT effects
in the eradication of malignant cells after myeloablative
allogeneic HSCT led to the development of reduced inten-
sity (RIC) or truly nonmyeloablative conditioning regimens.
RIC allogeneic HSCT is associated with reduced regi-
men-related toxicities and reduced transplant-related
mortality rates. Therefore, it allows patients who are inel-
igible for conventional allogeneic HSCT to beneﬁt from the
potentially curative GVT effects of allogeneic HSCT.
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In this article, we would like to propose a brief review of
this type of allografting by focusing on the GVT effect, RIC
regimens commonly used, the kinetics of engraftment, the
incidence and impact of acute and chronic GVHD, and the
current results of RIC HSCT in speciﬁc diseases.
2. Deﬁnition and features of RIC allogeneic HSCT
2.1. Graft-versus-tumor effect
The concept of GVT effects after allogeneic HSCT is sup-
ported by several lines of clinical evidence: (1) patients
who develop graft-versus-host disease (GVHD) have a low-
er risk of relapse than those who do not, (2) patients given
T-cell depleted grafts or those given grafts from identical
twins have higher risks of relapse, and (3) donor lympho-
cyte infusions can induce complete remissions (CR) in a
number of patients who have relapsed hematological
malignancies after allogeneic HSCT [3,4].
It has been suggested that the main mechanisms of
GVT effects were the recognition of host-speciﬁc minor
or major histocompatibility antigens (and maybe tumor-
speciﬁc antigens) by donor T cells, although several obser-
vations have also suggested a role for donor NK and B
cells [5–9].
After RIC allogeneic HSCT, tumor eradication relies
partially (RIC regimens) or nearly entirely (truly non-
myeloablative regimens) on these GVT effects. Antitumor
responses may require extended periods of time, with
some patients achieving complete remission more than
1 year after HSCT. GVT activity may also vary in intensity
depending on the immunogenicity of the tumors and the
respective proliferation rates of tumor cells and donor im-
mune cells [10].
2.2. Nonmyeloablative versus reduced intensity conditioning
regimens
In comparison with conventional myeloablative condi-
tioning, RIC regimens have been developed with the aim
to induce only reversible myelosuppression and less non-
hematological toxicity. These regimens exert only low or
moderate activity against malignant cells but provide suf-
ﬁcient immune suppression to prevent immediate rejec-
tion of the graft and to allow GVT effects [11].
All RIC regimens should not be considered equivalent,
since their immunosuppressive and myelosuppressive
properties may be different. In particular, one can distin-
guish RIC regimens and truly nonmyeloablative regimens.
Most RIC regimens combine ﬂudarabine with interme-
diate doses of alkylating agents such as busulfan, melpha-
lan or thiothepa. These regimens limit graft rejection
(ﬂudarabine) but also convey major antitumor effects by
themselves with the aim of shrinking and controlling the
malignancy (alkylating agents) before the GVT effects can
occur [12]. Typical complications of high-dose therapy,
such as mucositis, pancytopenia and organ damage can
be observed with these RIC regimens but occur less fre-
quently than after myeloablative conditioning.
In contrast, nonmyeloablative regimens rely on optimi-
zation of pre- and post-transplant immunosuppression to
allow engraftment, while eradication of tumors depends
nearly exclusively on GVT effects. The most common non-
myeloablative regimen consist of low-dose (2 Gy) total
body irradiation (TBI) with or without ﬂudarabine com-
bined with postgrafting immunosuppression with myco-
phenolate mofetil (MMF) and cyclosporine (CSP). Other
regimens associate cyclophosphamide and ﬂudarabine,
or anti-thymocyte globulin (ATG) and total lymphoid irra-
diation (TLI) (8 Gy) with postgrafting immunosuppression
also consisting in MMF and CSP [12]. These types of con-
ditioning regimens produce only mild myelosuppression
and little regimen-related toxicity, making them realiz-
able in an outpatient setting [13]. Following nonmyeloab-
lative conditioning, antitumor responses may require
extended periods of time. Because of that, nonmyeloabla-
tive HSCT is generally not recommended for patients with
aggressive malignancies not in good response at the time
of HSCT.
It has been suspected that RIC regimens might be asso-
ciated with better survival than truly nonmyeloablative
conditioning because of a possibly lower incidence of re-
lapse and similar non-relapse mortality. However, two re-
cent studies have suggested that it might not be the case.
Blaise et al. reported the results of a prospective random-
ized study comparing outcomes of 139 patients with
hematological malignancies given grafts after ﬂudarabine,
busulfan (8 mg/kg) and ATG (n = 69) or ﬂudarabine and
2 Gy TBI (n = 70) [14]. With a median follow-up of 4 years,
overall survival (the primary endpoint of the study) was
similar in the two arms (44% versus 47%, respectively). Fur-
ther, Mohty et al. compared outcomes of patients with
acute myeloid leukemia (AML) in ﬁrst CR given grafts fol-
lowing low-dose TBI-based nonmyeloablative conditioning
(n = 323) versus more intense but still RIC regimens
(n = 877) in European group for Blood and Marrow Trans-
plantation (EBMT)-afﬁliated centers [15]. Two-year dis-
ease-free survival was similar in the two groups (50%
versus 53%, respectively).
2.3. Engraftment: mixed chimerism and risk of graft rejection
In contrast with allogeneic transplantation after
myeloablative conditioning, RIC HSCT usually leads to an
initial state of mixed chimerism deﬁned as the coexistence
in the bone marrow of hematopoietic cells from host and
from donor origin. Eventually, the majority of patients
evolve to full donor chimerism. Achievement of full donor
T-cell chimerism is strongly correlated with a decreased
risk of progression or relapse [16]. Therefore, attempts to
convert mixed chimerism into full donor chimerism (for
example by using donor lymphocyte infusions) should be
considered in some cases.
RIC HSCT is associated with a higher risk of graft rejec-
tion compared with conventional regimens. McSweeney
et al. reported a 20% graft rejection rate 2–4 months after
HSCT with TBI alone as nonmyeloablative conditioning
regimen [17]. High levels (>50%) of donor T- and NK-cell
chimerism one month after transplantation are associated
with a lower risk of graft rejection [13].
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3. Transplantation-related morbidity
3.1. Graft-versus-host disease (GVHD)
A number of reports have compared the incidences of
acute and chronic GVHD after RIC and after myeloablative
allogeneic HSCT. Most have shown a lower incidence of
acute GVHD (when acute GVHD was deﬁned as GVHD
occurring before day 100) but a similar incidence of
chronic GVHD with RIC regimens [18]. The relatively re-
duced incidence and severity of acute GVHD after RIC
transplantation can be explained by the combination of
low-intensity pre-transplant conditioning and the initial
mixed chimerism that may favor both host-versus-graft
and graft-versus-host tolerance [17,18]. However, a num-
ber of patients given RIC conditioning experience late
acute GVHD (i.e. acute GVHD occurring after day 100), of-
ten at the time of conversion from mixed to full donor T-
cell chimerism [13,18].
Occurrence of GVHD is strongly associated with graft-
versus-tumor effects in patients given myeloablative con-
ditioning [2]. Since nonmyeloablative regimens rely nearly
exclusively on GVT effects for tumor eradication, several
groups of investigators looked at the impact of GVHD on
HSCT outcomes after nonmyeloablative or RIC condition-
ing. The Seattle group analyzed the impact of acute and
chronic GVHD on HSCT outcomes in a cohort of 322 pa-
tients given nonmyeloablative HSCT as treatment for vari-
ous hematological malignancies [16]. Grade II and grade
III–IV acute GVHD were not signiﬁcantly associated with
lower risks of progression/relapse, but were instead associ-
ated with increased non-relapse mortality and lower pro-
gression-free survival. In contrast, occurrence of chronic
GVHD correlated with lower risks of relapse in multivari-
ate time-dependent analyses (HR = 0.4, P = 0.006) and
was associated with signiﬁcantly better progression-free
survival (HR = 0.5, P = 0.003). Similar observations were re-
ported by Valcarcel et al., in a cohort of 93 patients given
grafts after RIC as treatment for AML or advanced myelo-
dysplastic syndrome (MDS) [19].
3.2. Other toxicities
The profound pancytopenia following myeloablative
conditioning is less profound after RIC regimens and pa-
tients require fewer platelet and red blood cell transfusions
[17,20].
In a high proportion of patients, neutrophil counts re-
main over 0.5  109 cells/L during the transplant period
or the duration of neutropenia is very short (median time
13 days) [20,21]. This is associated with a lower risk of
early bacteremia [21,22]. There is no difference in the inci-
dence of fungal infections after RIC transplantation com-
pared with myeloablative conditioning and CMV
manifestations are just delayed [21,22].
RIC regimens are well tolerated in terms of mucosal
toxicity and tissue (liver, kidney, gastrointestinal tract
and lung) damages are signiﬁcantly reduced (1, 23). Most
of them can also prevent some classical long-term toxicity
of conventional conditioning regimens (e.g. preservation of
fertility).
4. Outcomes and anti-tumoral activity
4.1. Comparison of outcomes after myeloablative or RIC
regimens
Three large retrospective studies from the EBMT have
compared HSCT outcomes of patients given various
myeloablative versus various RIC/nonmyeloablative regi-
mens as treatment for AML, MDS, or chronic lymphocytic
leukemia (CLL) (Table 1) [23–25]. Obviously these studies
are limited by the fact that ﬁtter patients were probably
more often proposed myeloablative regimens, while older
and sicker patients were given nonmyeloablative or RIC
regimens. Nevertheless, these studies found similar
disease-free and overall survivals in the two groups of
patients, since non-relapse mortality was lower in
nonmyeloablative patients, but relapse rates were lower
in myeloablative recipients [23–25].
4.2. Results in speciﬁc diseases
4.2.1. Acute leukemias
The largest prospective study of nonmyeloablative
HSCT as treatment for AML has been recently reported by
the Seattle consortium for 274 patients with AML in ﬁrst
(n = 160) or second (n = 71) CR or with more advanced dis-
eases (n = 43) [26]. The conditioning regimen consisted in
ﬂudarabine and 2 Gy TBI. Five-year overall survival was
37% for patients in ﬁrst CR at the time of HSCT, 34% for
those in second CR and 18% for those with more advanced
disease. Other factors associated with survival included
cytogenetic risk (5-year overall survival of 40% for patients
with good/intermediate cytogenetics versus 19% for those
with poor risk cytogenetics), and chronic GVHD that was
associated with better survival in time-dependent analysis
(HR = 0.7, P = 0.07, due to a 50% reduction in the risk of re-
Table 1
Retrospective studies comparing HSCT outcomes of patients given grafts after nonmyeloablative/RIC or myeloablative conditioning.
Authors
(reference)
Disease Relapse (HR (95%CI); P
value)
Non-relapse mortality (HR (95%CI), P
value)
Progression-free survival (HR (95%CI), P
value)
Aoudjhane [23] AML 1.78 (1.30–2.43); 0.0003 0.48 (0.33–0.68);<0.001 1.15 (0.90–1.47); 0.24
Martino [25] MDS 1.64 (1.20–2.20); 0.001 0.61 (0.41–0.91); 0.015 1.10 (0.80–1.40); 0.9
Dreger [24] CLL 2.46 (0.90–6.72); 0.08 0.40 (0.18–0.90); 0.03 0.69 (0.38–1.25); 0.22
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; HR, hazard ratio.
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lapse (P = 0.01)). The later observations clearly demon-
strate that AML is highly susceptible to GVT effects.
Nonmyeloablative or RIC HSCT is also increasingly used
as treatment for patients with acute lymphoblastic leuke-
mia (ALL). Interestingly, preliminary data from two retro-
spective studies (one from the CIBMTR and one from the
EBMT) have showed similar survival in ALL patients given
RIC/nonmyeloablative conditioning compared with those
given myeloablative conditioning [27]. These encouraging
results conﬁrm the existence of graft-versus-ALL effects.
4.2.2. Myelodysplastic syndromes and myeloproliferative
disorders
Martino et al. reported the outcomes of 215 patients gi-
ven one of various RIC or nonmyeloablative conditioning
regimens as treatment for MDS (refractory anemia
(n = 20) or more advanced MDS (n = 195)) in EBMT-afﬁli-
ated centers [25]. Three-year incidences of relapse and
non-relapse mortality were 45% and 22%, respectively,
while 3-year overall survival was 41%. These results seem
to be better than those reported by Laport et al. in patients
with MDS given grafts after 2 Gy TBI alone or with ﬂudar-
abine (3-year relapse rate of 41% and 3-year overall sur-
vival of 27%), perhaps due to a high incidence of graft
rejection among previously untreated patients given low-
intensity nonmyeloablative conditioning [28].
More recently, Kroger et al. reported the results of a
prospective study of RIC allogeneic HSCT as treatment for
103 patients with myeloﬁbrosis [29]. The conditioning reg-
imen consisted in busulfan (10 mg/kg), ﬂudarabine and
ATG. The 5-year incidence of relapse was 29%, while 5-year
progression-free and overall survivals were 51% and 67%,
respectively.
4.2.3. Lymphomas
A number of studies have evaluated HSCT following re-
duced intensity or nonmyeloablative conditioning regi-
mens as treatment for patients with advanced
lymphoma, including those relapsing after autologous
HSCT [30–33]. Graft-versus-tumor effects were particu-
larly impressive in patients with indolent or mantle cell
lymphoma, as well as in those with chemosensitive aggres-
sive lymphomas [10]. Further, two recent reports demon-
strated that some patients with Hodgkin’s lymphoma
relapsing after autologous HSCT could be salvaged with
nonmyeloablative/RIC allo-HSCT [34].
4.2.4. Chronic lymphocytic leukemia
Sorror et al. described outcomes in 152 patients (med-
ian age 60 years) with CLL (40) or lymphoma (112) who re-
ceived HSCT from HLA-matched related (n = 84) or
unrelated (n = 68) donors after conditioning with 2 Gy
TBI alone or combined with ﬂudarabine [35]. With a med-
ian follow-up of 4 years, the 3-year rate of non-relapse
mortality was 25%, while 3-year overall survival was 53%.
These results demonstrate that CLL is remarkably suscepti-
ble to GVT effects, and that a signiﬁcant proportion of pa-
tients with ﬂudarabine-refractory CLL might be cured by
RIC/nonmyeloablative HSCT.
4.2.5. Multiple myeloma
The role of nonmyeloablative HSCT in patients with
multiple myeloma has been controversial. The Intergroupe
Francophone du Myelome compared the outcomes of 284
patients with high risk multiple myeloma treated in two
separate prospective protocols consisting of either double
autologous HSCT or single autologous HSCT followed by
RIC allogeneic HSCT [36]. Survival was worse in the autol-
ogous/allogeneic arm but this might be due to the fact that
allografting was preceded by administration of high doses
of ATG that could have abrogated graft-versus-myeloma
effects. Bruno et al. compared a protocol that entailed an
autologous HSCT followed by an allograft from an HLA-
identical sibling (following conditioning with 2 Gy TBI)
for all patients with a HLA-identical sibling with a protocol
of tandem autologous HSCT for patients without a HLA-
identical sibling [37]. After a median follow-up of
45 months, median overall and event-free survivals were
longer in the 80 patients with than in the 82 patients with-
out HLA-identical siblings (80 months versus 54 months,
P = 0.01; and 35 months versus 29 months, P = 0.02,
respectively). Similar results have been reported in an
EBMT-sponsored prospective trial using similar condition-
ing for autologous and allogeneic HSCT [38].
5. Perspectives
Further improvements in the outcome of RIC-HSCT re-
quire reinforcing GVT effects while limiting the deleterious
effects of GVHD, and in particular acute GVHD.
Strategies aimed at increasing GVT effects are investi-
gating combining disease-targeted therapies such as imati-
nib, thalidomide, bortezomib, rituximab, azacytidine, or
radiolabeled monoclonal antibodies as part of the prepara-
tive regimen or as maintenance strategies.
One of the biggest challenges for the future of RIC allo-
geneic HSCT will be to develop protocols to better prevent
acute GVHD. Potential approaches include various forms of
T-cell depletion of the graft or in vivo T-cell depletion, as
well as the use of immuno-regulatory cells such as mesen-
chymal stem cells, NK/T cells, or regulatory T cells.
Nonmyeloablative HSCT with CD8-depleted grafts has
been evaluated by several groups, resulting in a lower
incidence of severe acute GVHD [39]. However, in a re-
cent phase II prospective randomized trial comparing
patients receiving unmanipulated or CD8-depleted grafts
after nonmyeloablative conditioning, Willems et al. re-
ported a similar incidence of acute GVHD, albeit with less
severe acute GVHD, but a higher risk of graft rejection in
the CD8-depleted arm [40]. Based on similar concepts,
other groups have proposed to reduce GVHD after RIC
conditioning by performing in vivo T-cell depletion with
ATG or alemtuzumab. These protocols have achieved their
goal but have been associated with a higher risk of re-
lapse [41].
Another approach aimed at reducing the incidence of
acute GVHD has been developed by the Stanford group.
Based on murine experiments, the authors investigated a
novel nonmyeloablative regimen that favored the presence
of a high proportion of regulatory NK–T cells [42]. This
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regimen consisted of TLI (8 Gy) and ATG (Thymoglobulin,
7.5 mg/kg total dose), and postgrafting immunosuppres-
sion with MMF and CSP. The ﬁrst results in 110 patients
with various hematological malignancies indicated that
this regimen was indeed associated with a low incidence
of grade II–IV acute GVHD (<10%), while GVT effects were
apparently preserved.
Other strategies aimed at decreasing the incidence of
acute GVHD have focused on mesenchymal stem cells
(MSC). MSC are multipotent progenitors within the bone
marrow capable of differentiating into various connective
tissues and of modulating immune responses by inhibiting
T-cell proliferation. Several groups have evaluated the po-
tential of MSC infusions to prevent or to treat acute GVHD
after allogeneic HSCT [43]. Recently, Baron et al. have
investigated the impact on GVHD occurence of MSC
co-infusion in 20 patients receiving HLA-mismatched
allogeneic grafts after nonmyeloablative conditioning
[44]. Compared with 16 similar historical controls, MSC
co-transplantation was associated with a lower inci-
dence of severe acute GVHD, lower NRM and improved
survival.
Other potential avenues for limiting the risk of acute
GVHD are based on regulatory T cells (Treg). These immu-
no-regulatory cells are thought to promote allogeneic tol-
erance. Rezvani et al. have suggested that the graft Treg
content and the rate of Treg reconstitution after transplan-
tation may predict the risk of GVHD after HSCT with
myeloablative conditioning [45]. Therefore, manipulating
Treg numbers early after transplantation may provide a
new approach to control acute GVHD in myeloablative as
well as RIC settings. Treg infusions after transplantation as
well as Treg number expansion by immunoregulatory drugs
such as rapamycine are under investigation.
6. Conclusion
Reduced intensity conditioning (RIC) regimens have al-
lowed performing allogeneic hematopoietic stem cell
transplantation (HSCT) in patients for whom conventional
myeloablative allogeneic HSCT would have been associ-
ated with unacceptable risks of non-relapse mortality. This
approach relies mainly on graft-versus-tumor effects for
tumor eradication. Results after RIC HSCT are generally
encouraging in patient with acute myeloid leukemia in
complete remission, with myelodysplastic syndromes not
in transformation, with indolent and chemotherapy-sensi-
tive aggressive lymphoma and with chronic lymphoid leu-
kemia. At the opposite, advanced aggressive diseases such
as acute leukemia not in complete remission, chemother-
apy-refractory high-grade lymphoma or multiple myeloma
are less responsive to this therapeutic approach alone. For
such diseases, previous cytoreduction by chemotherapy or
autologous HSCT is generally required. Occurrence of
chronic GVHD seems to correlate with a lower risk of re-
lapse and better progression-free survival. However, acute
GVHD is not associated with GVT effects after non-
myeloablative conditioning and remains a serious compli-
cation of RIC HSCT. Current research attempts at
developing new methods to control it.
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